Pharmaceutical
Engineering
Chemicals

Cambrex

$40.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.63 (-1.52%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Cambrex and other stocks, options, ETFs, and crypto commission-free!

About

Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Read More Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.

Employees
1,732
Headquarters
East Rutherford, New Jersey
Founded
1981
Market Cap
1.40B
Price-Earnings Ratio
17.49
Dividend Yield
0.00
Average Volume
382.82K
High Today
$41.34
Low Today
$40.63
Open Price
$41.08
Volume
25.70K
52 Week High
$69.43
52 Week Low
$33.80

Collections

Pharmaceutical
Engineering
Chemicals
Therapy
Health
US
North America

News

Yahoo FinanceMay 10

Can Cambrex Run Higher on Rising Earnings Estimates?

Cambrex (CBM) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. Analysts' growing optimism on the earnings prospects of this life sciences company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings esti...

15
TradingNewsNowMay 9

Current Performance: Cambrex Corporation (NYSE: CBM)

Cambrex Corporation trades as part of the biotechnology industry and healthcare sector. The company CEO is Steven M. Klosk. Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. Previous Intraday Trading Performance: The CBM stock showed a previous change of -0.44% with an open at 44.87 and a close of 44.84. It reache...

10
Seeking AlphaMay 5

Cambrex Corporation (CBM) CEO Steven Klosk on Q1 2019 Results - Earnings Call Transcript

Cambrex Corporation (NYSE:CBM) Q1 2019 Earnings Conference Call May 2, 2019 8:30 AM ET Company Participants Gregory Sargen - Chief Financial Officer and Executive Vice President, Corporate Development and Strategy Steven Klosk - President and Chief Executive Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC John Kreger - William Blair & Company LLC David Windley - Jefferies LLC Evan Stover - Robert W. Baird & Co. Steve Schwartz - First Analysis Securities Corporat...

18

Earnings

$0.32
$0.69
$1.07
$1.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.